image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 2.5601
-1.91 %
$ 3.43 M
Market Cap
-2.59
P/E
1. INTRINSIC VALUE

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds.[ Read More ]

The intrinsic value of one SNOA stock under the base case scenario is HIDDEN Compared to the current market price of 2.56 USD, Sonoma Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SNOA

image
FINANCIALS
12.7 M REVENUE
-4.05%
-4.7 M OPERATING INCOME
-2.87%
-4.84 M NET INCOME
6.13%
-2.4 M OPERATING CASH FLOW
61.02%
-2 K INVESTING CASH FLOW
99.22%
1.68 M FINANCING CASH FLOW
-32.66%
3.58 M REVENUE
5.54%
-850 K OPERATING INCOME
27.54%
-610 K NET INCOME
46.63%
354 K OPERATING CASH FLOW
138.82%
-26 K INVESTING CASH FLOW
-420.00%
1.44 M FINANCING CASH FLOW
127.04%
Balance Sheet Decomposition Sonoma Pharmaceuticals, Inc.
image
Current Assets 12.5 M
Cash & Short-Term Investments 3.13 M
Receivables 2.9 M
Other Current Assets 6.52 M
Non-Current Assets 2.19 M
Long-Term Investments 0
PP&E 651 K
Other Non-Current Assets 1.54 M
Current Liabilities 3.72 M
Accounts Payable 607 K
Short-Term Debt 719 K
Other Current Liabilities 2.39 M
Non-Current Liabilities 4.88 M
Long-Term Debt 87 K
Other Non-Current Liabilities 4.8 M
EFFICIENCY
Earnings Waterfall Sonoma Pharmaceuticals, Inc.
image
Revenue 12.7 M
Cost Of Revenue 7.99 M
Gross Profit 4.74 M
Operating Expenses 9.45 M
Operating Income -4.7 M
Other Expenses 134 K
Net Income -4.84 M
RATIOS
37.26% GROSS MARGIN
37.26%
-36.91% OPERATING MARGIN
-36.91%
-37.97% NET MARGIN
-37.97%
-78.78% ROE
-78.78%
-32.80% ROA
-32.80%
-67.86% ROIC
-67.86%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Sonoma Pharmaceuticals, Inc.
image
Net Income -4.84 M
Depreciation & Amortization 176 K
Capital Expenditures -17 K
Stock-Based Compensation 516 K
Change in Working Capital 1.69 M
Others 2.18 M
Free Cash Flow -2.42 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Sonoma Pharmaceuticals, Inc.
image
SNOA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Sonoma Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
6 years ago
Mar 13, 2018
Bought 4.92 K USD
Miller Robert E
Chief Financial Officer
+ 1200
4.0996 USD
6 years ago
Mar 12, 2018
Bought 4.84 K USD
Miller Robert E
Chief Financial Officer
+ 1200
4.03 USD
6 years ago
Mar 12, 2018
Bought 4.84 K USD
Miller Robert E
Chief Financial Officer
+ 1200
4.03 USD
6 years ago
Mar 09, 2018
Bought 4.68 K USD
Miller Robert E
Chief Financial Officer
+ 1200
3.9 USD
6 years ago
Mar 08, 2018
Bought 9.87 K USD
Schutz James J
Chief Executive Officer
+ 2473
3.99 USD
6 years ago
Nov 30, 2017
Bought 1.71 K USD
Schutz James J
Chief Executive Officer
+ 345
4.95 USD
6 years ago
Nov 29, 2017
Bought 6.48 K USD
Miller Robert E
Chief Financial Officer
+ 1290
5.02 USD
6 years ago
Nov 29, 2017
Bought 2.52 K USD
Miller Robert E
Chief Financial Officer
+ 500
5.03 USD
6 years ago
Nov 29, 2017
Bought 2.01 K USD
Schutz James J
Chief Executive Officer
+ 400
5.03 USD
6 years ago
Nov 24, 2017
Bought 1.28 K USD
Schutz James J
Chief Executive Officer
+ 254
5.05 USD
6 years ago
Nov 21, 2017
Bought 2.52 K USD
Miller Robert E
Chief Financial Officer
+ 500
5.04 USD
6 years ago
Nov 21, 2017
Bought 7.54 K USD
Miller Robert E
Chief Financial Officer
+ 1500
5.03 USD
7 years ago
Aug 10, 2017
Bought 12 K USD
Miller Robert E
Chief Financial Officer
+ 2264
5.3 USD
7 years ago
Aug 10, 2017
Bought 3.19 K USD
Umscheid Marc
Chief Strategy/Mkt Officer
+ 600
5.31 USD
7 years ago
Aug 10, 2017
Bought 5.07 K USD
Schutz James J
Chief Executive Officer
+ 929
5.4569 USD
7 years ago
Mar 09, 2017
Bought 1.78 K USD
Miller Robert E
Chief Financial Officer
+ 250
7.14 USD
7 years ago
Mar 09, 2017
Bought 1.74 K USD
Miller Robert E
Chief Financial Officer
+ 250
6.96 USD
7 years ago
Mar 09, 2017
Bought 1.74 K USD
Miller Robert E
Chief Financial Officer
+ 250
6.97 USD
7 years ago
Mar 08, 2017
Bought 5.23 K USD
Miller Robert E
Chief Financial Officer
+ 750
6.97 USD
7 years ago
Mar 08, 2017
Bought 1.7 K USD
Miller Robert E
Chief Financial Officer
+ 250
6.81 USD
7 years ago
Mar 06, 2017
Bought 5.12 K USD
Umscheid Marc
Chief Strategy/Mkt Officer
+ 750
6.82 USD
7 years ago
Mar 03, 2017
Bought 702 USD
Schutz James J
Chief Executive Officer
+ 104
6.75 USD
7 years ago
Mar 03, 2017
Bought 4.72 K USD
Schutz James J
Chief Executive Officer
+ 696
6.78 USD
7 years ago
Dec 08, 2016
Bought 24.3 K USD
Miller Robert E
Chief Financial Officer
+ 5000
4.86 USD
7 years ago
Dec 08, 2016
Bought 4.88 K USD
Schutz James J
Chief Executive Officer
+ 1000
4.88 USD
8 years ago
Aug 15, 2016
Bought 4.87 K USD
Schutz James J
Chief Executive Officer
+ 1328
3.6639 USD
8 years ago
Feb 25, 2016
Bought 5 K USD
Schutz James J
Chief Executive Officer
+ 5000
0.9999 USD
11 years ago
Aug 16, 2013
Bought 12 K USD
Schutz James J
Chief Executive Officer
+ 5100
2.35 USD
11 years ago
Dec 07, 2012
Bought 65 USD
Alimi Hojabr
Chief Executive Officer
+ 100
0.65 USD
11 years ago
Dec 07, 2012
Bought 1.43 K USD
Alimi Hojabr
Chief Executive Officer
+ 2200
0.6489 USD
11 years ago
Dec 07, 2012
Bought 1.3 K USD
Alimi Hojabr
Chief Executive Officer
+ 2000
0.6476 USD
11 years ago
Dec 07, 2012
Bought 650 USD
Alimi Hojabr
Chief Executive Officer
+ 1000
0.65 USD
11 years ago
Dec 10, 2012
Bought 1.6 K USD
Alimi Hojabr
Chief Executive Officer
+ 2500
0.6393 USD
11 years ago
Dec 10, 2012
Bought 1.91 K USD
Alimi Hojabr
Chief Executive Officer
+ 3000
0.6364 USD
11 years ago
Dec 06, 2012
Bought 2.55 K USD
Alimi Hojabr
Chief Executive Officer
+ 4000
0.6373 USD
11 years ago
Dec 06, 2012
Bought 1.9 K USD
Alimi Hojabr
Chief Executive Officer
+ 3000
0.6329 USD
11 years ago
Dec 06, 2012
Bought 629 USD
Alimi Hojabr
Chief Executive Officer
+ 1000
0.6292 USD
11 years ago
Dec 06, 2012
Bought 626 USD
Alimi Hojabr
Chief Executive Officer
+ 1000
0.6256 USD
12 years ago
Nov 09, 2012
Bought 780 USD
Schutz James J
Chief Operating Officer
+ 1000
0.78 USD
12 years ago
Nov 09, 2012
Bought 400 USD
Schutz James J
Chief Operating Officer
+ 500
0.8 USD
12 years ago
Nov 09, 2012
Bought 9.12 K USD
Schutz James J
Chief Operating Officer
+ 11400
0.8 USD
12 years ago
Nov 09, 2012
Bought 80 USD
Schutz James J
Chief Operating Officer
+ 100
0.8 USD
14 years ago
Aug 09, 2010
Bought 22.3 K USD
Schutz James J
Chief Operating Officer
+ 11680
1.91 USD
14 years ago
Aug 09, 2010
Bought 12.6 K USD
Schutz James J
Chief Operating Officer
+ 6820
1.85 USD
14 years ago
Jun 10, 2010
Bought 6.01 K USD
French Gregory M
Chief Operating Officer
+ 3020
1.991 USD
14 years ago
Jun 07, 2010
Bought 6.22 K USD
French Gregory M
Chief Operating Officer
+ 3076
2.023 USD
14 years ago
Mar 10, 2010
Sell 47.3 K USD
Alimi Hojabr
Chief Executive Officer
- 15000
3.1562 USD
14 years ago
Dec 09, 2009
Bought 3.33 K USD
Schutz James J
Chief Operating Officer
+ 1890
1.76 USD
14 years ago
Dec 09, 2009
Bought 6.18 K USD
Schutz James J
Chief Operating Officer
+ 3490
1.77 USD
14 years ago
Dec 09, 2009
Bought 35.8 USD
Schutz James J
Chief Operating Officer
+ 20
1.79 USD
14 years ago
Dec 09, 2009
Bought 26.3 K USD
Schutz James J
Chief Operating Officer
+ 14600
1.8 USD
15 years ago
Nov 11, 2009
Bought 3.3 K USD
Miller Robert E
Chief Financial Officer
+ 2000
1.6499 USD
15 years ago
Nov 11, 2009
Bought 3.3 K USD
Miller Robert E
Chief Financial Officer
+ 2000
1.6499 USD
15 years ago
Nov 10, 2009
Bought 3.06 K USD
Miller Robert E
Chief Financial Officer
+ 1800
1.6999 USD
15 years ago
Nov 10, 2009
Bought 340 USD
Miller Robert E
Chief Financial Officer
+ 200
1.7 USD
15 years ago
Nov 10, 2009
Bought 1.53 K USD
Miller Robert E
Chief Financial Officer
+ 900
1.6999 USD
15 years ago
Nov 10, 2009
Bought 3.06 K USD
Miller Robert E
Chief Financial Officer
+ 1800
1.6999 USD
15 years ago
Nov 10, 2009
Bought 510 USD
Miller Robert E
Chief Financial Officer
+ 300
1.7 USD
15 years ago
Nov 10, 2009
Bought 3.4 K USD
Miller Robert E
Chief Financial Officer
+ 2000
1.7 USD
15 years ago
Nov 10, 2009
Bought 3.34 K USD
Miller Robert E
Chief Financial Officer
+ 2000
1.6699 USD
15 years ago
Aug 10, 2009
Sell 333 K USD
Alimi Hojabr
Chief Executive Officer
- 150000
2.2192 USD
15 years ago
Aug 10, 2009
Sell 325 K USD
Alimi Hojabr
Chief Executive Officer
- 165000
1.9721 USD
15 years ago
Jun 01, 2009
Bought 502 K USD
Burlingame Robert
Director
+ 444445
1.13 USD
15 years ago
Jun 01, 2009
Bought 623 K USD
Burlingame Robert
Director
+ 333333
1.87 USD
15 years ago
Jun 01, 2009
Bought 667 K USD
Burlingame Robert
Director
+ 569801
1.17 USD
15 years ago
Mar 06, 2009
Sell 13.9 K USD
Alimi Hojabr
Chief Executive Officer
- 13200
1.0495 USD
15 years ago
Mar 04, 2009
Bought 251 K USD
Burlingame Robert
Director
+ 222222
1.13 USD
15 years ago
Mar 04, 2009
Bought 312 K USD
Burlingame Robert
Director
+ 166667
1.87 USD
15 years ago
Mar 04, 2009
Bought 255 K USD
Burlingame Robert
Director
+ 218234
1.17 USD
15 years ago
Mar 03, 2009
Sell 7.65 K USD
Alimi Hojabr
Chief Executive Officer
- 6200
1.2336 USD
15 years ago
Mar 04, 2009
Sell 20.6 K USD
Alimi Hojabr
Chief Executive Officer
- 17800
1.1555 USD
15 years ago
Mar 05, 2009
Sell 8.92 K USD
Alimi Hojabr
Chief Executive Officer
- 7800
1.144 USD
16 years ago
Mar 07, 2008
Sell 80.4 K USD
Alimi Hojabr
Chief Executive Officer
- 15000
5.36 USD
16 years ago
Dec 07, 2007
Bought 31.5 K USD
Schutz James J
Vice President
+ 6750
4.67 USD
16 years ago
Dec 07, 2007
Bought 14.9 K USD
Schutz James J
Vice President
+ 3250
4.59 USD
17 years ago
Jan 30, 2007
Bought 78.1 K USD
French Gregory M
Director
+ 10000
7.8067 USD
7. News
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel BOULDER, CO / ACCESSWIRE / November 11, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microcyn technology-based hydrogel, including improved biocompatibility and extended shelf life. Per this new clearance, Sonoma's Microdacyn® Hydrogel can be used under the supervision of a healthcare professional for management of wounds associated with dermal irritation, sores, injuries and ulcers of dermal tissue, for use on first and second degree burns, and diabetic ulcers, and for the management of mechanically or surgically debrided wounds. accesswire.com - 5 days ago
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results Revenue increased 31% for the quarter compared to same period prior year Positive cash flows from operations of $0.35 million for the quarter Net loss improved 59% for the quarter compared to same period prior year Net loss per share improved 90% for the quarter compared to same period prior year BOULDER, CO / ACCESSWIRE / November 7, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced financial results for its second fiscal quarter ended September 30, 2024. "Our results this quarter reflect the diligent efforts by Sonoma's team to grow our business and drive toward profitability," said Amy Trombly, CEO of Sonoma. accesswire.com - 1 week ago
Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf BOULDER, CO / ACCESSWIRE / October 31, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it will be exhibiting at MEDICA 2024 in Düsseldorf, Germany November 11-14, 2024. MEDICA is considered the largest and most prestigious medical trade fair in the world, expected to attract over 120,000 visitors from more than 70 countries and over 5,300 exhibitors, showcasing the latest innovations in medical technology, diagnostics, and healthcare IT. accesswire.com - 2 weeks ago
Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada BOULDER, CO / ACCESSWIRE / October 22, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it has entered into an amendment to its distribution agreement with a leading global healthcare distributor for the marketing and distribution of its wound care products in Canada. As previously announced, on August 19, 2024, Sonoma entered into a distribution agreement with a global healthcare distributor for the marketing and distribution of its wound care products in the United States, to be sold through hospital systems and other healthcare channels. accesswire.com - 3 weeks ago
Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule BOULDER, CO / ACCESSWIRE / September 19, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it received a formal determination letter from Nasdaq notifying Sonoma that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market and the matter is now closed. As previously reported, On September 22, 2023, Sonoma received a letter from Nasdaq indicating that it did not comply with the $1.00 minimum closing bid price requirement for its common stock for continued listing on the Nasdaq Capital Market. accesswire.com - 1 month ago
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution BOULDER, CO / ACCESSWIRE / September 17, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microcyn technology-based solution, including specific over-the-counter indications for the face, eyelid and eyelashes. Per this new clearance, Sonoma's Microcyn wound care solution can be used for OTC management of minor skin abrasions, lacerations and irritations, and intact skin on the face, eyelid and eyelashes. accesswire.com - 1 month ago
Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line BOULDER, CO / ACCESSWIRE / September 11, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, in partnership with EMC Pharma, LLC, today announced they have entered into a co-marketing agreement to launch and sell an expanded prescription and OTC eye care product line. The new eye care line will also feature refreshed design and improved packaging for Ocucyn® Eyelid & Eyelash Cleanser. accesswire.com - 2 months ago
Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock BOULDER, CO / ACCESSWIRE / August 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the timing for a 1-for-20 reverse split of its outstanding common stock which will be effected on August 29, 2024 at 5:00 pm EDT. Sonoma common stock will begin trading on The Nasdaq Capital Market on a 1-for-20 adjusted basis when the market opens on August 30, 2024. accesswire.com - 2 months ago
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff BOULDER, CO / ACCESSWIRE / August 26, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, and its partner, the MicroSafe Group DMCC, announce that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for Nanocyn® Disinfectant and Sanitizer, which is manufactured by Sonoma for its partner MicroSafe using Sonoma's patented Microcyn® technology. Nanocyn® was previously approved by the TGA and entered into The Australian Register of Therapeutic Goods with a 15 second kill time against SARS-CoV-2 (COVID 19), and a 30 second kill time against Norovirus (Gastro), Influenza A (H1N1), and bacteria, such as Staphylococcus aureus (MRSA), E. accesswire.com - 2 months ago
Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States BOULDER, CO / ACCESSWIRE / August 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it has entered into a distribution agreement with a leading global healthcare distributor for the marketing and distribution of its wound care products in the United States. The agreement provides for the distribution of Sonoma's wound care products through an existing and extensive network of hospital systems and other healthcare channels in the United States. accesswire.com - 2 months ago
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2025 Financial Results European revenues increased 20% compared to same period last year Gross margin of 39% compared to 35% in same period last year Net loss improved 19% compared to same period last year BOULDER, CO / ACCESSWIRE / August 8, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended June 30, 2024. "This year marks the twentieth anniversary of the introduction of Sonoma wound care products into Europe; it is remarkable how our business has expanded and diversified in that time," remarked Amy Trombly, CEO of Sonoma. accesswire.com - 3 months ago
Sonoma Pharmaceuticals (SNOA) Is Attractively Priced Despite Fast-paced Momentum Sonoma Pharmaceuticals (SNOA) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices. zacks.com - 4 months ago
8. Profile Summary

Sonoma Pharmaceuticals, Inc. SNOA

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 3.43 M
Dividend Yield 0.00%
Description Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Contact 645 Molly Lane, Woodstock, GA, 30189 https://www.sonomapharma.com
IPO Date Jan. 25, 2007
Employees 10
Officers Mr. Bruce Thornton Executive Vice President, Chief Operating Officer & Corporate Secretary Ms. Amy M. Trombly Chief Executive Officer, President & Director Mr. Jerome J. Dvonch Chief Financial Officer Mr. John Dal Poggetto Controller